Follow Us:

IVDR CE Marking

Home Post Market Performance Follow Up
Quick Contact
Post Market Performance Follow Up

Post Market Performance Follow Up

Post Market Performance Follow Up (PMPF) is a continuous process that updates the performance evaluation outlined in Article 56 and Part A of Annex XIII. The post-market performance follow-up is intended to confirm the device’s safety, efficacy, and validity throughout the device’s expected lifetime after it has been marketed and to ensure that the benefit-risk ratio remains acceptable and that emerging risks are identified using factual evidence. PMPF must be performed using a documented method outlined in a PMPF plan.

Why Post Market Performance Follow Up?

Post Market Performance follow up is necessary to confirm the device’s safety and performance throughout its expected lifetime. To identify risks that were previously unknown, performance limitations, and contraindications. To identify and analyse emergent risks based on factual evidence. To ensure the continuous acceptability of the clinical evidence and the benefit-risk ratio mentioned in Sections 1 and 8 of Chapter I of Annex I, and to detect potential systematic misuse.

Do you need an email containing full details within 2 minutes?

The Conduct of Post Market Performance Follow Up

The following aspects should be considered when conducting PMPF:


  • PMPF plan
  • General methods and procedures of PMPF, such as collecting user feedback forms, analysing complaints for further improvements, scientific literature, and other sources of performance or scientific data.
  • Specific methods and procedures of PMPF, such as ring trials and other quality assurance activities, epidemiological research, the evaluation of appropriate patient or disease registers, genetic databanks, and post-market clinical performance studies.
  • A justification for the suitability of general or specific methods and procedures.
  • A reference to the relevant sections of the performance evaluation report (Annex XIII, Section 1.3) and risk management (Annex I, Section 3).
  • The PMPF’s specific objectives.
  • An evaluation of performance data for equivalent or similar devices, as well as state-of-the-art.
  • Reference to any applicable CS, harmonized standards when applied by the manufacturer, and relevant PMPF guidelines.
  • A detailed and well-justified schedule for PMPF activities, such as data analysis and reporting.
  • The manufacturer must analyse the PMPF findings and document the results in a PMPF evaluation report that will be used to update the performance evaluation report and as part of the technical documentation.
  • If the PMPF identifies the need for preventive and/or corrective measures, the manufacturer must implement them
  • IVDR requires ongoing reporting in the form of PMPF Report


A rationale must be included and recorded in the performance evaluation report if PMPF isn’t considered to be appropriate for a particular device

PMPF and Role of Consultants

Consultants offer continuous support and guidance to ensure compliance with IVDR regulations. Such as assisting with regulatory submissions, addressing regulatory queries, and managing modifications as per regulatory requirements.


In order to maintain the safety and efficacy of in vitro diagnostic medical devices (IVDs), consultants assist manufacturers in identifying and addressing potential risks related to post-market performance. They can also assist in the development of risk management strategies and mitigation measures

IVDR extension will end by May 2027 quickly approaching, it’s time for manufacturers to start planning how they will address the new PMPF requirements. I3CGLOBAL and their professionals develop PMPF plans that align with your performance evaluation reports (PERs) and strengthen areas of weakness in performance evidence
Frequently Asked Questions

What is Performance Evidence Matrix?

The initiation of each PMPF project involves the development of a performance evidence matrix, which organizes and evaluates existing data to validate indications and claims by IVDR regulations. Collaboration between subject matter experts and medical writers proficient in clinical and regulatory domains leads to the creation of this matrix. Consequently, the resulting document effectively highlights deficiencies in performance evidence, facilitating the identification and resolution of pertinent gaps.

Buy Risk Analysis Procedure & Templates

Very useful for small and medium size medical device manufactures

IVDR Technical Documentation Support

Find how we can be helpful for your team